Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 420

1.

Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.

Bard JM, Lassalle R, Capeau J, Bach-Ngohou K, Nazih-Sanderson F, Rémy G, Reynes J, Ecobichon JL, Savès M, Raffi F; Aproco-Copilote Study Group.

Antivir Ther. 2006;11(3):361-70.

PMID:
16759053
2.
3.
5.

Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.

Arnedo M, Taffé P, Sahli R, Furrer H, Hirschel B, Elzi L, Weber R, Vernazza P, Bernasconi E, Darioli R, Bergmann S, Beckmann JS, Telenti A, Tarr PE; Swiss HIV Cohort Study.

Pharmacogenet Genomics. 2007 Sep;17(9):755-64.

PMID:
17700364
6.

Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.

Rimland D, Guest JL, Hernández I, Del Rio C, Le NA, Brown WV.

HIV Med. 2005 Sep;6(5):326-33.

7.

Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy.

Vigouroux C, Maachi M, Nguyên TH, Coussieu C, Gharakhanian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum W, Capeau J, Bastard JP.

AIDS. 2003 Jul 4;17(10):1503-11.

PMID:
12824788
8.

Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.

Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T.

Pediatrics. 2002 Nov;110(5):e56.

PMID:
12415062
9.

An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients.

Fauvel J, Bonnet E, Ruidavets JB, Ferrières J, Toffoletti A, Massip P, Chap H, Perret B.

AIDS. 2001 Dec 7;15(18):2397-406.

PMID:
11740190
11.

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.

Negredo E, Ribalta J, Paredes R, Ferré R, Sirera G, Ruiz L, Salazar J, Reiss P, Masana L, Clotet B.

AIDS. 2002 Jul 5;16(10):1383-9.

PMID:
12131215
12.
13.
14.

Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients.

Badiou S, Thiebaut R, Aurillac-Lavignolle V, Dabis F, Laporte F, Cristol JP, Mercie P; Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA).

J Infect. 2008 Jul;57(1):47-54. doi: 10.1016/j.jinf.2008.05.007. Epub 2008 Jun 12.

PMID:
18554723
15.

Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.

Tarr PE, Taffé P, Bleiber G, Furrer H, Rotger M, Martinez R, Hirschel B, Battegay M, Weber R, Vernazza P, Bernasconi E, Darioli R, Rickenbach M, Ledergerber B, Telenti A; Swiss HIV Cohort Study.

J Infect Dis. 2005 May 1;191(9):1419-26. Epub 2005 Mar 22. Erratum in: J Infect Dis. 2005 Jun 1;191(11):1997.

16.

Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy.

Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N.

Int J STD AIDS. 2001 Jul;12(7):463-8.

PMID:
11394983
18.

A cross-sectional study of lipids and ApoC levels in Alzheimer's patients with and without cardiovascular disease.

Adunsky A, Chesnin V, Davidson M, Gerber Y, Alexander K, Haratz D.

J Gerontol A Biol Sci Med Sci. 2002 Nov;57(11):M757-61.

PMID:
12403806
20.

Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype.

Shahmanesh M, Jaleel H, DeSilva Y, Ross JD, Caslake M, Cramb R.

Sex Transm Infect. 2001 Aug;77(4):283-6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk